Related Experiment Video

Updated: Jul 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Targeted therapy in colorectal cancer

Scott Wadler1

  • 1Weill Medical College of Cornell University, New York, NY, USA. scw2004@optonline.net

Clinical Colorectal Cancer
|February 22, 2007
PubMed

Insights

Adjuvant therapy, including monoclonal antibodies like bevacizumab, cetuximab, and panitumumab, improves outcomes for colorectal cancer patients. Combination therapies enhance clinical results beyond single treatments.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Adjuvant therapy is crucial for reducing disease recurrence in stages II-IV colorectal cancer.
  • Monoclonal antibodies represent a significant advancement in improving patient outcomes.
  • Understanding the mechanisms of targeted therapies is key to optimizing cancer treatment.

Purpose of the Study:

  • To review the efficacy of adjuvant monoclonal antibodies in colorectal cancer.
  • To highlight the roles of bevacizumab, cetuximab, and panitumumab.
  • To assess the benefits of combination therapies.

Main Methods:

  • Review of clinical and preclinical data on monoclonal antibodies.
  • Analysis of antiangiogenesis and EGFR-targeted agents.
  • Evaluation of combination therapy outcomes.

Main Results:

  • Bevacizumab, an antiangiogenesis agent, shows activity in adjuvant and metastatic settings.
  • Cetuximab and panitumumab target the epidermal growth factor receptor.
  • Combination therapies of monoclonal antibodies and chemotherapy yield superior clinical outcomes.

Conclusions:

  • Monoclonal antibodies are effective adjuvant treatments for colorectal cancer.
  • Targeted therapies offer new avenues for disease management.
  • Combined treatment strategies improve overall patient prognosis.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.